Verastem Inc (VSTM)

$7.70 +0.96 (14.24%)
Market Cap 370.36M
Revenue (ttm) 10.00M
Net Income (ttm) -130.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,306.40%
Debt to Equity Ratio -2.20
Volume 6,974,800
Avg Vol 2,595,590
Day's Range N/A - N/A
Shares Out 54.95M
Stochastic %K 95%
Beta 0.83
Analysts Strong Sell
Price Target $15.25

Company Profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 292 4200
Address:
117 Kendrick Street, Suite 500, Needham, United States
Vanderm98
Vanderm98 Aug. 12 at 2:51 AM
$VSTM Ok, when it launched I was thinking 20, 10, 5 , 2 on a percentage follow through before basing. We’re at 19, 14. Volume is increasing. It kind of looks like it wants to run a little more. BWTFDIK. GL.
0 · Reply
Vanderm98
Vanderm98 Aug. 12 at 2:40 AM
$VSTM This one’s for Ned. GLTA
0 · Reply
amarkwell
amarkwell Aug. 12 at 1:24 AM
$VSTM thinking about the poor bastard who sold 45k shares because he thought this was going sub $5. I fell your pain
0 · Reply
DreyOfAllTrades
DreyOfAllTrades Aug. 12 at 12:30 AM
$VSTM can you pass $BTAI tomorrow...
0 · Reply
bmac6687
bmac6687 Aug. 11 at 11:46 PM
$VSTM Where you at @JoeDirty?
1 · Reply
Benioffnyc
Benioffnyc Aug. 11 at 10:04 PM
$VSTM I hope they dont kill this momentum with a offering.
1 · Reply
boston_drew
boston_drew Aug. 11 at 9:48 PM
$VSTM notice how the stock melts up at EOD vs prior to earnings it would go down this will be the new trend
0 · Reply
Airbags
Airbags Aug. 11 at 7:29 PM
$TNXP not gonna lie.. I was tempted to sell this morning and buy $VSTM bc of their .. kicking myself now.. but TNXP is gold too..
1 · Reply
Get_Out
Get_Out Aug. 11 at 6:54 PM
$VSTM this smells like a winner didn’t sell at 8 last time around. prob won’t again this time either
2 · Reply
Avocado_smash
Avocado_smash Aug. 11 at 6:53 PM
$VSTM
1 · Reply
Latest News on VSTM
Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 8:55 PM EDT - 3 days ago

Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Aug 7, 2025, 4:05 PM EDT - 4 days ago

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 29, 2025, 7:30 AM EDT - 13 days ago

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Jul 24, 2025, 7:30 AM EDT - 18 days ago

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Verastem: The Market Is Ignoring The Progress

Jul 16, 2025, 8:22 AM EDT - 26 days ago

Verastem: The Market Is Ignoring The Progress

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Jul 11, 2025, 4:12 PM EDT - 4 weeks ago

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 8, 2025, 7:30 AM EDT - 4 weeks ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Jun 30, 2025, 4:02 PM EDT - 6 weeks ago

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers

Jun 26, 2025, 11:16 AM EDT - 6 weeks ago

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Jun 24, 2025, 4:02 PM EDT - 6 weeks ago

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

Jun 2, 2025, 9:40 AM EDT - 2 months ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 7:30 AM EDT - 2 months ago

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

May 22, 2025, 5:01 PM EDT - 2 months ago

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

May 20, 2025, 8:30 AM EDT - 2 months ago

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

TEM

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

May 13, 2025, 4:34 PM EDT - 3 months ago

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8, 2025, 1:17 PM EDT - 3 months ago

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

U.S. FDA approves Verastem's cancer therapy

May 8, 2025, 12:23 PM EDT - 3 months ago

U.S. FDA approves Verastem's cancer therapy

Verastem Oncology to Present at Upcoming Investor Conferences

May 1, 2025, 7:30 AM EDT - 3 months ago

Verastem Oncology to Present at Upcoming Investor Conferences

Verastem Oncology Announces $75 million Private Placement

Apr 25, 2025, 9:00 AM EDT - 3 months ago

Verastem Oncology Announces $75 million Private Placement

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Apr 23, 2025, 4:05 PM EDT - 3 months ago

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination

Apr 10, 2025, 2:35 PM EDT - 4 months ago

Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Mar 25, 2025, 4:35 PM EDT - 4 months ago

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Mar 20, 2025, 4:01 PM EDT - 5 months ago

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Feb 20, 2025, 4:05 PM EST - 6 months ago

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Jan 29, 2025, 7:30 AM EST - 6 months ago

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Jan 23, 2025, 7:30 AM EST - 7 months ago

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Jan 15, 2025, 7:30 AM EST - 7 months ago

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Jan 14, 2025, 7:30 AM EST - 7 months ago

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Jan 13, 2025, 7:30 AM EST - 7 months ago

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Verastem: Planning The PDUFA Run-Up

Jan 3, 2025, 11:56 AM EST - 7 months ago

Verastem: Planning The PDUFA Run-Up

Verastem: BLA Acceptance Puts Key Goals In Sight

Jan 2, 2025, 11:39 AM EST - 7 months ago

Verastem: BLA Acceptance Puts Key Goals In Sight

Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?

Dec 31, 2024, 10:59 AM EST - 7 months ago

Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Dec 30, 2024, 4:30 PM EST - 8 months ago

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Dec 18, 2024, 7:30 AM EST - 8 months ago

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem: Preparing For Upcoming Catalysts

Nov 27, 2024, 1:28 PM EST - 9 months ago

Verastem: Preparing For Upcoming Catalysts

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 26, 2024, 7:00 AM EST - 9 months ago

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Nov 6, 2024, 4:05 PM EST - 9 months ago

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Oct 31, 2024, 4:01 PM EDT - 10 months ago

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology to Participate in Upcoming Investor Conferences

Oct 31, 2024, 7:30 AM EDT - 10 months ago

Verastem Oncology to Participate in Upcoming Investor Conferences

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Oct 17, 2024, 1:00 AM EDT - 10 months ago

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Oct 9, 2024, 6:00 AM EDT - 10 months ago

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

Sep 10, 2024, 4:05 PM EDT - 11 months ago

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting

Sep 10, 2024, 7:30 AM EDT - 11 months ago

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting

Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity

Sep 5, 2024, 11:21 PM EDT - 1 year ago

Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

Jul 29, 2024, 4:01 PM EDT - 1 year ago

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Jul 23, 2024, 11:20 PM EDT - 1 year ago

Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Jul 23, 2024, 4:05 PM EDT - 1 year ago

Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Vanderm98
Vanderm98 Aug. 12 at 2:51 AM
$VSTM Ok, when it launched I was thinking 20, 10, 5 , 2 on a percentage follow through before basing. We’re at 19, 14. Volume is increasing. It kind of looks like it wants to run a little more. BWTFDIK. GL.
0 · Reply
Vanderm98
Vanderm98 Aug. 12 at 2:40 AM
$VSTM This one’s for Ned. GLTA
0 · Reply
amarkwell
amarkwell Aug. 12 at 1:24 AM
$VSTM thinking about the poor bastard who sold 45k shares because he thought this was going sub $5. I fell your pain
0 · Reply
DreyOfAllTrades
DreyOfAllTrades Aug. 12 at 12:30 AM
$VSTM can you pass $BTAI tomorrow...
0 · Reply
bmac6687
bmac6687 Aug. 11 at 11:46 PM
$VSTM Where you at @JoeDirty?
1 · Reply
Benioffnyc
Benioffnyc Aug. 11 at 10:04 PM
$VSTM I hope they dont kill this momentum with a offering.
1 · Reply
boston_drew
boston_drew Aug. 11 at 9:48 PM
$VSTM notice how the stock melts up at EOD vs prior to earnings it would go down this will be the new trend
0 · Reply
Airbags
Airbags Aug. 11 at 7:29 PM
$TNXP not gonna lie.. I was tempted to sell this morning and buy $VSTM bc of their .. kicking myself now.. but TNXP is gold too..
1 · Reply
Get_Out
Get_Out Aug. 11 at 6:54 PM
$VSTM this smells like a winner didn’t sell at 8 last time around. prob won’t again this time either
2 · Reply
Avocado_smash
Avocado_smash Aug. 11 at 6:53 PM
$VSTM
1 · Reply
Avocado_smash
Avocado_smash Aug. 11 at 6:51 PM
$VSTM
0 · Reply
Lessomd1
Lessomd1 Aug. 11 at 6:19 PM
$VSTM 10000 sept 8 calls just bought
0 · Reply
AUgold
AUgold Aug. 11 at 6:11 PM
$VSTM liking the pps action, every dip gets bought up and moves pps higher. Glta
0 · Reply
gargoyl
gargoyl Aug. 11 at 6:03 PM
$BLRX 👀 2Qt ER Thursday morning -PDAC - Partners - Gloria and Arymid 🐈‍⬛ lists - Cash on hand - low float Hedge on $VSTM
0 · Reply
SuperPuncher
SuperPuncher Aug. 11 at 5:50 PM
$VSTM glad I did not sell more calls recently lol!
0 · Reply
boston_drew
boston_drew Aug. 11 at 5:36 PM
$VSTM plenty of time to buy this stock will go from hated to loved by investors in a week it will be double digits
2 · Reply
MrWaikoloa
MrWaikoloa Aug. 11 at 5:26 PM
$VSTM Looks like we see 8 today.
0 · Reply
CSIforme
CSIforme Aug. 11 at 5:02 PM
$VSTM If VS-7375 is approved in the future, it'll be a game changer for patients with pancreatic cancer! Not to mention, the bottom line for the company!
0 · Reply
hhclark07
hhclark07 Aug. 11 at 5:00 PM
$VSTM Train keep a rollin all night long....
0 · Reply
TripleWitch
TripleWitch Aug. 11 at 4:56 PM
$VSTM looks ready for the next leg up 🔥 🦵 🔥
0 · Reply
PharmaExpert
PharmaExpert Aug. 11 at 4:48 PM
$AKBA, $ARTL, $VSTM, $CLOV, $NLTX 🔥🔥🔥🔥🔥
0 · Reply
Unburdened
Unburdened Aug. 11 at 4:16 PM
$VSTM This is a long term holding. They will get bought out. Figure $14/$16 per share. 61M shares outstanding. With warrants I believe it is 90M shares. Not sure why this is so heavily shorted. Listen to the earnings CC and you will see this is an excellent management team.
4 · Reply